Promising Advances in Myasthenia Gravis Treatment and Pregnancy Outcomes – Insights from Nordic Evening at EAN 2024

Exciting developments in myasthenia gravis (MG) management include new, effective treatments with favorable safety profiles, such as complement inhibitors and FcRn blockers, offering rapid and meaningful improvements for moderate to severe disease. Additionally, recent data from Norway provides an optimistic message for patients with MG who wish to become pregnant, showing positive outcomes for both mothers and their children.